The MD Anderson expert discussed the main takeaway from the data published during the virtual AACR Annual Meeting, while looking forward to what comes next with these genetic drivers.
According to investigators, study findings could help guide treatment decisions and future research, as well as suggest new biomarkers for exploration.
The first-in-class inhibitor of connective tissue growth factor activity is being explored in combination with neoadjuvant gemcitabine and nab-paclitaxel as a potential method for downgrading unresectable locally advanced pancreatic cancer.